Clover Health Investments Corp (NASDAQ:CLOV) Q2 2022 Earnings Conference Call August 8, 2022 5:00 PM ET

Company Participants

Ryan Schmidt - IR

Vivek Garipalli - Co-Founder, CEO & Chairman

Andrew Toy - Co-Founder, President, & Director

Mark Herbers - Principal Accounting Officer

Conference Call Participants

Richard Close - Canaccord Genuity

Kevin Fischbeck - Bank of America Merrill Lynch

Jason Cassorla - Citigroup

Benjamin Mayo - SVB Securities

Gary Taylor - Cowen and Company

Operator

Ladies and gentlemen, good afternoon, and welcome to the Clover Health Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the prepared remarks. [Operator Instructions]. As a reminder today's call is being recorded.

I would now like to turn the call over to Ryan Schmidt, Investor Relations for Clover Health. Please go ahead.

Ryan Schmidt

Good afternoon, everyone. Joining me on the call today is our CEO, Vivek Garipalli; Andrew Toy, our President; and Mark Herbers, who served as our interim CFO during the second quarter. We will discuss first quarter results and answer your questions. This call is being recorded.

Before we get started, I would like to remind you that our second-quarter earnings materials, including the release, are available on our website at cloverhealth.com. I'd also like to caution you that we may make forward-looking statements during today's call that are subject to risks and uncertainties, including expectations about future performance. Factors that may cause actual results to differ materially from our expectations are detailed in our SEC filings, including in the Risk Factors section of our most recent Annual Report on Form 10-K and in our other SEC filings. Information about non-GAAP financial measures referenced including a reconciliation of those measures to GAAP measures can also be found in earnings materials available on our website.

With that, let me now turn over the call to Vivek.

Vivek Garipalli

Thanks, Ryan, and thanks, everyone, for joining us today. We continue to build upon our strong start to the year, with second-quarter results proving to be another positive step forward. We remain excited about the continued progress against our goals as well as the strategies we are laying out for 2023 and beyond. We believe that we can deliver above-average industry growth and improved margins, all by [indiscernible] primary care at scale, the assistant. Let me now cover the highlights from the second quarter before handing it over to Andrew for a more in-depth discussion.